From FDG and beyond: the evolving potential of nuclear medicine

Kenji Hirata; Koji Kamagata; Daiju Ueda; Masahiro Yanagawa; Mariko Kawamura; Takeshi Nakaura; Rintaro Ito; Fuminari Tatsugami; Yusuke Matsui; Akira Yamada; Yasutaka Fushimi; Taiki Nozaki; Shohei Fujita; Tomoyuki Fujioka; Takahiro Tsuboyama; Noriyuki Fujima; Shinji Naganawa

doi:10.1007/s12149-023-01865-6

From FDG and beyond: the evolving potential of nuclear medicine

Kenji Hirata, Koji Kamagata, Daiju Ueda, Masahiro Yanagawa, Mariko Kawamura, Takeshi Nakaura, Rintaro Ito, Fuminari Tatsugami, Yusuke Matsui, Akira Yamada, Yasutaka Fushimi, Taiki Nozaki, Shohei Fujita, Tomoyuki Fujioka, Takahiro Tsuboyama, Noriyuki Fujima, Shinji Naganawa

Research output: Contribution to journal › Review article › peer-review

12 Citations (Scopus)

Abstract

The radiopharmaceutical 2-[fluorine-18]fluoro-2-deoxy-d-glucose (FDG) has been dominantly used in positron emission tomography (PET) scans for over 20 years, and due to its vast utility its applications have expanded and are continuing to expand into oncology, neurology, cardiology, and infectious/inflammatory diseases. More recently, the addition of artificial intelligence (AI) has enhanced nuclear medicine diagnosis and imaging with FDG-PET, and new radiopharmaceuticals such as prostate-specific membrane antigen (PSMA) and fibroblast activation protein inhibitor (FAPI) have emerged. Nuclear medicine therapy using agents such as [¹⁷⁷Lu]-dotatate surpasses conventional treatments in terms of efficacy and side effects. This article reviews recently established evidence of FDG and non-FDG drugs and anticipates the future trajectory of nuclear medicine.

Original language	English
Pages (from-to)	583-595
Number of pages	13
Journal	Annals of nuclear medicine
Volume	37
Issue number	11
DOIs	https://doi.org/10.1007/s12149-023-01865-6
Publication status	Published - Nov 2023

Keywords

Artificial neural
Data analysis
Fibroblast activation protein inhibitor
Fluorodeoxyglucose
Positron emission tomography
Prostate-specific membrane antigen

ASJC Scopus subject areas

Radiology Nuclear Medicine and imaging

Access to Document

10.1007/s12149-023-01865-6

Cite this

Hirata, K., Kamagata, K., Ueda, D., Yanagawa, M., Kawamura, M., Nakaura, T., Ito, R., Tatsugami, F., Matsui, Y., Yamada, A., Fushimi, Y., Nozaki, T., Fujita, S., Fujioka, T., Tsuboyama, T., Fujima, N., & Naganawa, S. (2023). From FDG and beyond: the evolving potential of nuclear medicine. Annals of nuclear medicine, 37(11), 583-595. https://doi.org/10.1007/s12149-023-01865-6

Hirata, K, Kamagata, K, Ueda, D, Yanagawa, M, Kawamura, M, Nakaura, T, Ito, R, Tatsugami, F, Matsui, Y, Yamada, A, Fushimi, Y, Nozaki, T, Fujita, S, Fujioka, T, Tsuboyama, T, Fujima, N & Naganawa, S 2023, 'From FDG and beyond: the evolving potential of nuclear medicine', Annals of nuclear medicine, vol. 37, no. 11, pp. 583-595. https://doi.org/10.1007/s12149-023-01865-6

@article{d6a78ece773641cdb03b3965818f0417,

title = "From FDG and beyond: the evolving potential of nuclear medicine",

abstract = "The radiopharmaceutical 2-[fluorine-18]fluoro-2-deoxy-d-glucose (FDG) has been dominantly used in positron emission tomography (PET) scans for over 20 years, and due to its vast utility its applications have expanded and are continuing to expand into oncology, neurology, cardiology, and infectious/inflammatory diseases. More recently, the addition of artificial intelligence (AI) has enhanced nuclear medicine diagnosis and imaging with FDG-PET, and new radiopharmaceuticals such as prostate-specific membrane antigen (PSMA) and fibroblast activation protein inhibitor (FAPI) have emerged. Nuclear medicine therapy using agents such as [177Lu]-dotatate surpasses conventional treatments in terms of efficacy and side effects. This article reviews recently established evidence of FDG and non-FDG drugs and anticipates the future trajectory of nuclear medicine.",

keywords = "Artificial neural, Data analysis, Fibroblast activation protein inhibitor, Fluorodeoxyglucose, Positron emission tomography, Prostate-specific membrane antigen",

author = "Kenji Hirata and Koji Kamagata and Daiju Ueda and Masahiro Yanagawa and Mariko Kawamura and Takeshi Nakaura and Rintaro Ito and Fuminari Tatsugami and Yusuke Matsui and Akira Yamada and Yasutaka Fushimi and Taiki Nozaki and Shohei Fujita and Tomoyuki Fujioka and Takahiro Tsuboyama and Noriyuki Fujima and Shinji Naganawa",

note = "Publisher Copyright: {\textcopyright} 2023, The Author(s) under exclusive licence to The Japanese Society of Nuclear Medicine.",

year = "2023",

month = nov,

doi = "10.1007/s12149-023-01865-6",

language = "English",

volume = "37",

pages = "583--595",

journal = "Annals of nuclear medicine",

issn = "0914-7187",

publisher = "Springer",

number = "11",

}

TY - JOUR

T1 - From FDG and beyond

T2 - the evolving potential of nuclear medicine

AU - Hirata, Kenji

AU - Kamagata, Koji

AU - Ueda, Daiju

AU - Yanagawa, Masahiro

AU - Kawamura, Mariko

AU - Nakaura, Takeshi

AU - Ito, Rintaro

AU - Tatsugami, Fuminari

AU - Matsui, Yusuke

AU - Yamada, Akira

AU - Fushimi, Yasutaka

AU - Nozaki, Taiki

AU - Fujita, Shohei

AU - Fujioka, Tomoyuki

AU - Tsuboyama, Takahiro

AU - Fujima, Noriyuki

AU - Naganawa, Shinji

PY - 2023/11

Y1 - 2023/11

N2 - The radiopharmaceutical 2-[fluorine-18]fluoro-2-deoxy-d-glucose (FDG) has been dominantly used in positron emission tomography (PET) scans for over 20 years, and due to its vast utility its applications have expanded and are continuing to expand into oncology, neurology, cardiology, and infectious/inflammatory diseases. More recently, the addition of artificial intelligence (AI) has enhanced nuclear medicine diagnosis and imaging with FDG-PET, and new radiopharmaceuticals such as prostate-specific membrane antigen (PSMA) and fibroblast activation protein inhibitor (FAPI) have emerged. Nuclear medicine therapy using agents such as [177Lu]-dotatate surpasses conventional treatments in terms of efficacy and side effects. This article reviews recently established evidence of FDG and non-FDG drugs and anticipates the future trajectory of nuclear medicine.

AB - The radiopharmaceutical 2-[fluorine-18]fluoro-2-deoxy-d-glucose (FDG) has been dominantly used in positron emission tomography (PET) scans for over 20 years, and due to its vast utility its applications have expanded and are continuing to expand into oncology, neurology, cardiology, and infectious/inflammatory diseases. More recently, the addition of artificial intelligence (AI) has enhanced nuclear medicine diagnosis and imaging with FDG-PET, and new radiopharmaceuticals such as prostate-specific membrane antigen (PSMA) and fibroblast activation protein inhibitor (FAPI) have emerged. Nuclear medicine therapy using agents such as [177Lu]-dotatate surpasses conventional treatments in terms of efficacy and side effects. This article reviews recently established evidence of FDG and non-FDG drugs and anticipates the future trajectory of nuclear medicine.

KW - Artificial neural

KW - Data analysis

KW - Fibroblast activation protein inhibitor

KW - Fluorodeoxyglucose

KW - Positron emission tomography

KW - Prostate-specific membrane antigen

UR - http://www.scopus.com/inward/record.url?scp=85172373252&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85172373252&partnerID=8YFLogxK

U2 - 10.1007/s12149-023-01865-6

DO - 10.1007/s12149-023-01865-6

M3 - Review article

C2 - 37749301

AN - SCOPUS:85172373252

SN - 0914-7187

VL - 37

SP - 583

EP - 595

JO - Annals of nuclear medicine

JF - Annals of nuclear medicine

IS - 11

ER -

From FDG and beyond: the evolving potential of nuclear medicine

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this